Reversal of left ventricular hypertrophy following treatment with beta-blockers: Experience with tertatolol

B. Trimarco, B. Ricciardelli, N. de Luca, A. Cuocolo, M. Volpe, G. Lembo, M. Condorelli

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hypertrophy in response to increasing blood pressure in primary hypertension leads to important functional consequences for the left ventricle. In fact, the progression of hypertensive heart disease, from an adaptive left ventricular hypertrophy with compensated ventricular function to severe hypertrophy with left ventricular failure, has been long thought to be related to the severity and duration of hypertension. Antihypertensive treatment seems to prevent or minimize the occurrence of left ventricular hypertrophy, but questions arise as to whether this therapy is also able to restore normal hemodynamic conditions, or at least to minimize the hemodynamic abnormalities. This review aims at summarizing current knowledge on the effects of the antihypertensive treatment with β-blockers, including tertatolol, on hypertension-induced left ventricular hypertrophy. The pathogenetic mechanisms underlying the cardiovascular changes associated with hypertension are discussed. A decrease in left ventricular wall thickness as well as in left ventricular mass has been reported in most of the studies performed with different types of β-adrenergic blocking agents. The extent of this reduction seems to be related not only to the fall in systemic blood pressure, but also to a decrease in sympathetic stimulation. With regard to the functional consequences of hypertension, the reversal of left ventricular hypertrophy following antihypertensive treatment with β-blockers is usually associated with an improvement in left ventricular performance. This phenomenon can hardly be ascribed to the direct effects of β-blocking agents. It is more likely to be related to the concomitant reduction in the afterload and to the improved left ventricular compliance, associated with a decrease in left ventricular wall thickness.

Original languageEnglish
Pages (from-to)94-99
Number of pages6
JournalAmerican Journal of Nephrology
Volume6
Issue numberSUPPL. 2
Publication statusPublished - 1986

Fingerprint

tertatolol
Left Ventricular Hypertrophy
Hypertension
Antihypertensive Agents
Hemodynamics
Blood Pressure
Adrenergic Antagonists
Ventricular Function
Hypertrophy
Compliance
Heart Ventricles
Heart Diseases

ASJC Scopus subject areas

  • Nephrology

Cite this

Trimarco, B., Ricciardelli, B., de Luca, N., Cuocolo, A., Volpe, M., Lembo, G., & Condorelli, M. (1986). Reversal of left ventricular hypertrophy following treatment with beta-blockers: Experience with tertatolol. American Journal of Nephrology, 6(SUPPL. 2), 94-99.

Reversal of left ventricular hypertrophy following treatment with beta-blockers : Experience with tertatolol. / Trimarco, B.; Ricciardelli, B.; de Luca, N.; Cuocolo, A.; Volpe, M.; Lembo, G.; Condorelli, M.

In: American Journal of Nephrology, Vol. 6, No. SUPPL. 2, 1986, p. 94-99.

Research output: Contribution to journalArticle

Trimarco, B, Ricciardelli, B, de Luca, N, Cuocolo, A, Volpe, M, Lembo, G & Condorelli, M 1986, 'Reversal of left ventricular hypertrophy following treatment with beta-blockers: Experience with tertatolol', American Journal of Nephrology, vol. 6, no. SUPPL. 2, pp. 94-99.
Trimarco, B. ; Ricciardelli, B. ; de Luca, N. ; Cuocolo, A. ; Volpe, M. ; Lembo, G. ; Condorelli, M. / Reversal of left ventricular hypertrophy following treatment with beta-blockers : Experience with tertatolol. In: American Journal of Nephrology. 1986 ; Vol. 6, No. SUPPL. 2. pp. 94-99.
@article{544ec7636e764683af2f4d46667a854f,
title = "Reversal of left ventricular hypertrophy following treatment with beta-blockers: Experience with tertatolol",
abstract = "Hypertrophy in response to increasing blood pressure in primary hypertension leads to important functional consequences for the left ventricle. In fact, the progression of hypertensive heart disease, from an adaptive left ventricular hypertrophy with compensated ventricular function to severe hypertrophy with left ventricular failure, has been long thought to be related to the severity and duration of hypertension. Antihypertensive treatment seems to prevent or minimize the occurrence of left ventricular hypertrophy, but questions arise as to whether this therapy is also able to restore normal hemodynamic conditions, or at least to minimize the hemodynamic abnormalities. This review aims at summarizing current knowledge on the effects of the antihypertensive treatment with β-blockers, including tertatolol, on hypertension-induced left ventricular hypertrophy. The pathogenetic mechanisms underlying the cardiovascular changes associated with hypertension are discussed. A decrease in left ventricular wall thickness as well as in left ventricular mass has been reported in most of the studies performed with different types of β-adrenergic blocking agents. The extent of this reduction seems to be related not only to the fall in systemic blood pressure, but also to a decrease in sympathetic stimulation. With regard to the functional consequences of hypertension, the reversal of left ventricular hypertrophy following antihypertensive treatment with β-blockers is usually associated with an improvement in left ventricular performance. This phenomenon can hardly be ascribed to the direct effects of β-blocking agents. It is more likely to be related to the concomitant reduction in the afterload and to the improved left ventricular compliance, associated with a decrease in left ventricular wall thickness.",
author = "B. Trimarco and B. Ricciardelli and {de Luca}, N. and A. Cuocolo and M. Volpe and G. Lembo and M. Condorelli",
year = "1986",
language = "English",
volume = "6",
pages = "94--99",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Reversal of left ventricular hypertrophy following treatment with beta-blockers

T2 - Experience with tertatolol

AU - Trimarco, B.

AU - Ricciardelli, B.

AU - de Luca, N.

AU - Cuocolo, A.

AU - Volpe, M.

AU - Lembo, G.

AU - Condorelli, M.

PY - 1986

Y1 - 1986

N2 - Hypertrophy in response to increasing blood pressure in primary hypertension leads to important functional consequences for the left ventricle. In fact, the progression of hypertensive heart disease, from an adaptive left ventricular hypertrophy with compensated ventricular function to severe hypertrophy with left ventricular failure, has been long thought to be related to the severity and duration of hypertension. Antihypertensive treatment seems to prevent or minimize the occurrence of left ventricular hypertrophy, but questions arise as to whether this therapy is also able to restore normal hemodynamic conditions, or at least to minimize the hemodynamic abnormalities. This review aims at summarizing current knowledge on the effects of the antihypertensive treatment with β-blockers, including tertatolol, on hypertension-induced left ventricular hypertrophy. The pathogenetic mechanisms underlying the cardiovascular changes associated with hypertension are discussed. A decrease in left ventricular wall thickness as well as in left ventricular mass has been reported in most of the studies performed with different types of β-adrenergic blocking agents. The extent of this reduction seems to be related not only to the fall in systemic blood pressure, but also to a decrease in sympathetic stimulation. With regard to the functional consequences of hypertension, the reversal of left ventricular hypertrophy following antihypertensive treatment with β-blockers is usually associated with an improvement in left ventricular performance. This phenomenon can hardly be ascribed to the direct effects of β-blocking agents. It is more likely to be related to the concomitant reduction in the afterload and to the improved left ventricular compliance, associated with a decrease in left ventricular wall thickness.

AB - Hypertrophy in response to increasing blood pressure in primary hypertension leads to important functional consequences for the left ventricle. In fact, the progression of hypertensive heart disease, from an adaptive left ventricular hypertrophy with compensated ventricular function to severe hypertrophy with left ventricular failure, has been long thought to be related to the severity and duration of hypertension. Antihypertensive treatment seems to prevent or minimize the occurrence of left ventricular hypertrophy, but questions arise as to whether this therapy is also able to restore normal hemodynamic conditions, or at least to minimize the hemodynamic abnormalities. This review aims at summarizing current knowledge on the effects of the antihypertensive treatment with β-blockers, including tertatolol, on hypertension-induced left ventricular hypertrophy. The pathogenetic mechanisms underlying the cardiovascular changes associated with hypertension are discussed. A decrease in left ventricular wall thickness as well as in left ventricular mass has been reported in most of the studies performed with different types of β-adrenergic blocking agents. The extent of this reduction seems to be related not only to the fall in systemic blood pressure, but also to a decrease in sympathetic stimulation. With regard to the functional consequences of hypertension, the reversal of left ventricular hypertrophy following antihypertensive treatment with β-blockers is usually associated with an improvement in left ventricular performance. This phenomenon can hardly be ascribed to the direct effects of β-blocking agents. It is more likely to be related to the concomitant reduction in the afterload and to the improved left ventricular compliance, associated with a decrease in left ventricular wall thickness.

UR - http://www.scopus.com/inward/record.url?scp=0022975753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022975753&partnerID=8YFLogxK

M3 - Article

C2 - 2879479

AN - SCOPUS:0022975753

VL - 6

SP - 94

EP - 99

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - SUPPL. 2

ER -